Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancer.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Surgical Outcomes from Nationwide Implementation of the International Best-Practice for Locally Advanced Pancreatic Cancer (PREOPANC-4) study.

The British journal of surgery·2026
Same author

Beyond non-anatomical resections: Is minimally invasive parenchyma-sparing anatomical hepatectomy the next chapter?

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Delayed gastric emptying after robot-assisted pancreatoduodenectomy: the Transatlantic Robot Pancreas Consortium (TROPANC).

Surgical endoscopy·2026
Same author

Surgical technique for fully robotic two-stage hepatectomy using indocyanine green fluorescence imaging for bilobar colorectal liver metastases.

Journal of visualized surgery·2026
Same author

Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation of prognostic models.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026

Related Experiment Video

Updated: Jul 14, 2026

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
13:35

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Published on: March 21, 2021

Sarcopenia does not affect total liver function measured using technetium-99m mebrofenin hepatobiliary scintigraphy.

Pieter Arntz1, Pim Olthof2,3, Fadi Rassam2

  • 1Cancer Center Amsterdam, Amsterdam UMC, Department of Surgery, University of Amsterdam, VUMC, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands. p.j.arntz@amsterdamumc.nl.

EJNMMI Research
|July 13, 2026
PubMed
Summary

Sarcopenia does not affect total liver function (TLF) measured by hepatobiliary scintigraphy (HBS). Decreased TLF is linked to older age, liver cancer, cirrhosis, and high bilirubin levels.

Keywords:
CancerHepatectomyLiver function testsRadionuclide imagingSarcopenia

Related Experiment Videos

Last Updated: Jul 14, 2026

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
13:35

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Published on: March 21, 2021

Area of Science:

  • Hepatobiliary imaging
  • Surgical oncology
  • Gastroenterology

Background:

  • Hepatobiliary scintigraphy (HBS) with technetium-99m mebrofenin estimates risks for major liver resections.
  • Sarcopenia is independently linked to poor surgical outcomes.
  • The study investigated factors influencing total liver function (TLF).

Purpose of the Study:

  • To correlate patient and disease factors, including sarcopenia, with TLF.
  • To assess the impact of sarcopenia on liver function estimation.
  • To identify predictors of reduced TLF in patients undergoing HBS.

Main Methods:

  • Retrospective cohort study.
  • Analysis of 346 patients undergoing HBS to quantify TLF.
  • Correlation analysis of body composition, patient demographics, and disease status with TLF.

Main Results:

  • Median TLF was 15.0 %/min.
  • Body composition parameters, including sarcopenia, did not correlate with TLF.
  • Older age, hepatocellular carcinoma, cirrhosis, and high bilirubin levels were associated with decreased TLF.
  • Absence of liver disease and good general health correlated with higher TLF.

Conclusions:

  • Sarcopenia does not influence TLF as measured by HBS.
  • TLF is negatively impacted by older age, hepatocellular carcinoma, cirrhosis, and elevated serum bilirubin.